We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eagle Pharmaceuticals, Inc. (EGRX), which went public last month, has as many as six candidates in its pipeline in addition to two approved products. The company, which raised more than $50...
Lannett Company, Inc. (LCI) is cashing in on generic drugs as it recently reported record sales and gross margins. This Zacks Rank #1 (Strong Buy) is expected to grow earnings by 329% in fiscal...
Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session with its shares rising over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal...
Galectin Therapeutics Inc.’s (GALT) carbohydrate-based galectin inhibitor GR-MD-02 is currently in phase I development for the treatment of nonalcoholic steatohepatitis (NASH) with...
Avanir Pharmaceuticals, Inc. (AVNR) announced preliminary results for the first quarter of fiscal 2014 (year ending in Sep 2014) with gross revenues of roughly $34.6 million ahead of the...
In a bid to strengthen its position in pet therapeutics, Aratana Therapeutics, Inc. (PETX) recently announced that it has acquired Belgium-based Okapi Sciences NV. Okapi owns a proprietary pet...
RedHill Biopharma Ltd. (RDHL) currently does not have any approved product in its portfolio and is making efforts to invest in the development of its late-stage candidates. RedHill Biopharma...
On Jan 2, 2014, Zacks Investment Research upgraded Gentium (GENT) to a Zacks Rank #1 (Strong Buy). Why the Upgrade? Shares of Gentium, an Italy-based biopharma company, have been on an...
GlaxoSmithKline (GSK) announced that it has completed the divestment of its thrombosis brands, Arixtra and Fraxiparine and nutritional drinks brands Lucozade and Ribena. We remind investors...
Galectin Therapeutics, Inc. (GALT) was a big mover last session, as the company saw its shares rise over 13% on the day. The move came on solid volume too with far more shares changing hands than...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions